Reduced CETP glycosylation and activity in patients with homozygous B4GALT1 mutations

Marjolein A. W. van den Boogert, Cleo L. Crunelle, Lubna Ali, Lars E. Larsen, Sacha D. Kuil, Johannes H. M. Levels, Alinda W. M. Schimmel, Vassiliki Konstantopoulou, Maryse Guerin, Jan Albert Kuivenhoven, Geesje M. Dallinga-Thie, Erik S. G. Stroes, Dirk J. Lefeber, Adriaan G. Holleboom

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

The importance of protein glycosylation in regulating lipid metabolism is becoming increasingly apparent. We set out to further investigate this by studying the effects of defective glycosylation on plasma lipids in patients with B4GALT1-CDG, caused by a mutation in B4GALT1 with defective N-linked glycosylation. We studied plasma lipids, cholesteryl ester transfer protein (CETP) glyco-isoforms with isoelectric focusing followed by a western blot and CETP activity in three known B4GALT1-CDG patients and compared them with 11 age- and gender-matched, healthy controls. B4GALT1-CDG patients have significantly lowered non-high density lipoprotein cholesterol (HDL-c) and total cholesterol to HDL-c ratio compared with controls and larger HDL particles. Plasma CETP was hypoglycosylated and less active in B4GALT1-CDG patients compared to matched controls. Our study provides insight into the role of protein glycosylation in human lipoprotein homeostasis. The hypogalactosylated, hypo-active CETP found in patients with B4GALT1-CDG indicates a role of protein galactosylation in regulating plasma HDL and LDL. Patients with B4GALT1-CDG have large HDL particles probably due to hypogalactosylated, hypo-active CETP.
Original languageEnglish
Pages (from-to)611-617
Number of pages7
JournalJournal of Inherited Metabolic Disease
Volume43
Issue number3
DOIs
Publication statusPublished - 1 May 2020

Keywords

  • B4GALT1
  • CDG
  • CETP
  • HDL
  • LDL
  • glycosylation
  • lipids

Cite this